Y-mabs announces nmpa submission of bla for danyelza® (naxitamab-gqgk) in china

New york, july 06, 2021 (globe newswire) -- y-mabs therapeutics, inc. (“y-mabs”, nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that sciclone pharmaceuticals (holdings) limited (“sciclone pharmaceuticals”) has submitted the biologics license application (“bla”) for danyelza® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma to the national medical products administration (“nmpa”) of china.
YMAB Ratings Summary
YMAB Quant Ranking